PT Saptausaha Gemilangindah Tbk (SAGE)
Jul 31, 2025 - SAGE was delisted (reason: acquired by SUPN)
8.68
-0.02 (-0.23%)
Inactive · Last trade price
on Jul 30, 2025
Sage Therapeutics Revenue
Sage Therapeutics had revenue of 139.11M IDR in the quarter ending June 30, 2025, a decrease of -97.16%. This brings the company's revenue in the last twelve months to 9.43B, down -49.71% year-over-year. In the year 2024, Sage Therapeutics had annual revenue of 16.89B, down -23.08%.
Revenue (ttm)
9.43B IDR
Revenue Growth
-49.71%
P/S Ratio
16.04
Revenue / Employee
26,713,280 IDR
Employees
353
Market Cap
9.32M USD
Revenue Chart
* This company reports financials in IDR.
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSAGE News
- 14 days ago - Sage Therapeutics Announces Second Quarter 2025 Financial Results - Business Wire
- 4 weeks ago - SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE - Business Wire
- 7 weeks ago - Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary - GlobeNewsWire
- 2 months ago - These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News - Benzinga
- 2 months ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect - Accesswire
- 2 months ago - Top 3 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga
- 2 months ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc. - PRNewsWire
- 2 months ago - Sage Therapeutics Stock Soars 35% After Sale to Supernus. What We Know. - Barrons